Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Including Bereavement in the Care Continuum.

2.

Adding cell-based vaccine to liver cancer therapy can slow cancer progression

3.

NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.

4.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

5.

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot